SCHEDULE 13G/A: Brown Capital Management Discloses 5.89% Stake in Cytek Biosciences

Brown Capital Management, LLC has filed an amended Schedule 13G, reporting a 5.89% beneficial ownership stake in Cytek Biosciences, Inc. as of March 31, 2025.

Summary

• Brown Capital Management, LLC filed an Amendment No. 2 to Schedule 13G concerning Cytek Biosciences, Inc. common stock (CUSIP: 23285D109).
• As of March 31, 2025, Brown Capital Management, LLC beneficially owns an aggregate of 7,463,967 shares of Cytek Biosciences, Inc.
• This ownership represents 5.89% of the total outstanding common stock of Cytek Biosciences, Inc.
• Brown Capital Management, LLC holds sole voting power over 3,337,125 shares and sole dispositive power over 7,463,967 shares.
• The shares are held on behalf of various investment advisory clients of Brown Capital Management, LLC.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant institutional stake is generally viewed as a positive signal of confidence in the company, although the document itself is a factual regulatory filing without performance data.

Positives

• A significant stake by a reputable investment firm like Brown Capital Management, LLC, may signal institutional confidence in Cytek Biosciences, Inc.'s long-term prospects.
• The filing explicitly states that the shares are held in the ordinary course of business, indicating a passive investment rather than an activist intent to influence control.

Future Outlook

NA

Industry Context

This filing reflects ongoing institutional investment activity within the biotechnology and life sciences sector, specifically in companies like Cytek Biosciences, which specializes in flow cytometry solutions. Such disclosures provide transparency into significant ownership positions by major investment firms.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be perceived positively, potentially boosting investor confidence and market sentiment for Cytek Biosciences, Inc.

Key Dates

Keywords

Cytek Biosciences, Brown Capital Management, Schedule 13G, beneficial ownership, common stock, institutional ownership, investment adviser, CYTK